ERBB2 and breast carcinoma: PALOMA-1 is an open-label, randomized cohort study where palbociclib plus letrozole was compared to letrozole alone as first-line treatment in 400 postmenopausal women with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.